Does rivaroxaban reduce the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in patients with a recent acute coronary syndrome?
In patients with a recent acute coronary syndrome, rivaroxaban reduces cardiovascular events but increases the risk of major and intracranial bleeding.
In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke. Rivaroxaban increased the risk of major bleeding and intracranial hemorrhage but not the risk of fatal bleeding. (Funded by Johnson ATLAS ACS 2-TIMI 51 ClinicalTrials.gov number, NCT00809965.).
Mega et al. (Sun,) studied this question.